Quilaban strengthens investment in reproductive medicine with new genetic diagnostic solution

Quilaban has established a partnership with Yikon Genomics to provide advanced genetic diagnostic technology applied to in vitro fertilisation in Portugal.

Quilaban has made new genetic diagnostic solutions in the field of reproductive medicine available on the Portuguese market through a partnership with Yikon Genomics. The introduction of this technology strengthens the capacity to support healthcare professionals involved in in vitro fertilisation treatments, in an area of constant technological and scientific evolution.

The solutions now integrated into Quilaban’s portfolio enable embryonic genetic analyses to be performed before transfer, providing relevant information for clinical decision-making.

In this regard, Yikon Genomics technology enables complete analysis of the 23 pairs of embryonic chromosomes, allowing early detection of genetic and structural alterations with relevant clinical impact, including chromosomal alterations and hereditary diseases. This approach contributes to more informed embryonic selection, increasing the probability of treatment success and reducing the risk of genetic disease transmission.

“The advancement of reproductive medicine requires increasingly robust, rapid and precise genetic diagnostic solutions, capable of supporting informed clinical decisions and increasing the probability of success in in vitro fertilisation treatments”, states Sónia Pereira, Product and Applications Manager at Quilaban.

In a context marked by the growth of medically assisted reproduction techniques, this technology also represents a response to current sector challenges, namely in terms of the speed and efficiency of laboratory processes. The availability of these solutions in Portugal enables reduction of dependence on international laboratories and optimisation of response times in clinical monitoring.

With this partnership, Quilaban reinforces its commitment to providing innovative solutions that contribute to the evolution of reproductive medicine and to better healthcare.